Literature DB >> 24654813

Opioid maintenance, weaning and detoxification techniques: where we have been, where we are now and what the future holds.

Anthony Plunkett1, Devon Kuehn, Mark Lenart, Indy Wilkinson.   

Abstract

SUMMARY Medically supervised opioid withdrawal is a complex and constantly evolving exercise in multimodal therapy that draws from the expertise of a variety of clinical specialties. Acute substitution and weaning has been performed utilizing opioid agonists, partial agonists (e.g., buprenorphine), mixed agonist/antagonists (e.g., Suboxone®), and α2 adrenergic agonists. While thousands of patients are being treated with these 'classic' opioid-withdrawal techniques, traditional treatment approaches are being challenged by the emergence of innovative techniques based on an understanding of the neurochemistry of addiction. Pharmacotherapy with controlled withdrawal is currently the most reliable method of opioid detoxification, but, as translational medicine continues to advance and genomic markers for opioid sensitivity and dependence are identified, the future shows great potential for growth and change.

Entities:  

Year:  2013        PMID: 24654813     DOI: 10.2217/pmt.13.24

Source DB:  PubMed          Journal:  Pain Manag        ISSN: 1758-1869


  2 in total

1.  Hypothesizing that a Pro-Dopaminergic Regulator (KB220z Liquid Variant) can Induce "Dopamine Homeostasis" and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence.

Authors:  Kenneth Blum; Debra Whitney; Lye Fried; Marcelo Febo; Roger L Waite; Eric R Braverman; Kristina Dushaj; Mona Li; John Giordano; Zsolt Demetrovics; Rajendra D Badgaiyan
Journal:  Clin Med Rev Case Rep       Date:  2016-08-16

2.  Association between opioid analgesic therapy and initiation of buprenorphine management: An analysis of prescription drug monitoring program data.

Authors:  Apostolos A Alexandridis; Nabarun Dasgupta; Christopher L Ringwalt; Wayne D Rosamond; Paul R Chelminski; Stephen W Marshall
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.